The molecular basis underlying Glioblastoma (GBM) heterogeneity and plasticity are not 26 fully understood. Using transcriptomic data of patient-derived brain tumor stem cell lines 27 (BTSCs), classified based on GBM-intrinsic signatures, we identify the AP-1 28 transcription factor FOSL1 as a master regulator of the mesenchymal (MES) subtype. We 29 provide a mechanistic basis to the role of the Neurofibromatosis type 1 gene (NF1), a 30 negative regulator of the RAS/MAPK pathway, in GBM mesenchymal transformation 31 through the modulation of FOSL1 expression. Depletion of FOSL1 in NF1-mutant human 32 BTSCs and Kras-mutant mouse neural stem cells results in loss of the mesenchymal gene 33 signature, reduction in stem cell properties and in vivo tumorigenic potential. Our data 34 demonstrate that FOSL1 controls GBM plasticity and aggressiveness in response to NF1 35 alterations. 36 37 Keywords 38 GBM, Mesenchymal, NF1, FOSL1, FRA-1, master regulator 39 40 Significance 41 Glioblastoma (GBM) is a very heterogenous disease for which multiple transcriptional 42 subtypes have been described. Among these subtypes, the Mesenchymal (MES) GBMs 43 have the worst prognosis. Here we provide the first causal evidence linking 44 Neurofibromatosis type 1 gene (NF1) signalling and the acquisition of a MES gene 45 expression program through the regulation of the AP-1 transcription factor FOSL1. Using 46 patient expression datasets, combined with in vitro and in vivo gain-and loss-of function 47
Summary 25
The molecular basis underlying Glioblastoma (GBM) heterogeneity and plasticity are not 26 fully understood. Using transcriptomic data of patient-derived brain tumor stem cell lines 27 (BTSCs), classified based on GBM-intrinsic signatures, we identify the AP-1 28 transcription factor FOSL1 as a master regulator of the mesenchymal (MES) subtype. We Glioblastoma (GBM) is a very heterogenous disease for which multiple transcriptional 42 subtypes have been described. Among these subtypes, the Mesenchymal (MES) GBMs 43 have the worst prognosis. Here we provide the first causal evidence linking 44
Neurofibromatosis type 1 gene (NF1) signalling and the acquisition of a MES gene 45 expression program through the regulation of the AP-1 transcription factor FOSL1. Using 46 patient expression datasets, combined with in vitro and in vivo gain-and loss-of function 47 mouse models, we show that FOSL1 is an important modulator of GBM that is required 48 and sufficient for the activation of a MES program. Our work sheds light on the 49 mechanisms that control the tumorigenicity of the most aggressive adult brain tumor type. 50
Introduction 51 Glioblastoma (GBM) , the most common and aggressive primary brain tumor in 52 adults, is characterized by high molecular and cellular inter-and intra-tumoral 53 heterogeneity. Large-scale sequencing approaches have evidenced how concurrent 54 perturbations of cell cycle regulators, growth and survival pathways, mediated by 55 RAS/MAPK and PI3K/AKT signaling, play a significant role in driving adult GBMs 56 (Brennan et al., 2013; The Cancer Genome Atlas Research Network, 2008; Verhaak et 57 al., 2010) . Moreover, various studies have classified GBM in different subtypes, using 58 transcriptional profiling, being now the Proneural (PN), Classical (CL) and Mesenchymal 59 (MES) the most widely accepted (Phillips et al., 2006; Verhaak et al., 2010; Wang et al., 60 2017) . 61
Patients with the MES subtype tend to have worse survival rates compared to other 62 subtypes, both in the primary and recurrent tumor settings (Wang et al., 2017) . The main 63 driver genetic alteration -Neurofibromatosis type 1 gene (NF1) copy number loss or 64 mutation -and important regulators of the MES subtype, such as STAT3, CEBPB and 65 TAZ, have been identified (Bhat et al., 2011; Carro et al., 2010; Verhaak et al., 2010) . 66
Nevertheless, the mechanisms of regulation of MES GBMs are still not fully understood. 67
For example, whether the MES transcriptional signature is controlled through tumor cell-68 intrinsic mechanisms or influenced by the tumor microenvironment (TME) is still an 69 unsolved question. In fact, the critical contribution of the TME adds another layer of 70 complexity to MES GBMs. Tumors from this subtype are highly infiltrated by non-71 neoplastic cells, as compared to PN and CL subtypes (Wang et al., 2017) . Additionally, 72 MES tumors express high levels of angiogenic markers and exhibit high levels of necrosis 73 (Cooper et al., 2012) . 74
Even though each subtype is associated with specific genetic alterations, there is 75 a considerable plasticity among them: different subtypes co-exist in the same tumors and 76 shifts in subtypes can occur over time (Patel et al., 2014; Sottoriva et al., 2013) . This 77 plasticity may be explained by acquisition of new genetic and epigenetic abnormalities, 78 by stem-like reprogramming or by clonal variation (Fedele et al., 2019) . It is also not fully 79 understood whether the distinct subtypes evolve from a common glioma precursor 80 (Ozawa et al., 2014) . For instance, PN tumors often switch phenotype to MES upon 81 recurrence, and treatment also increases the mesenchymal gene signature, suggesting that 82 MES transition, or epithelial to mesenchymal (EMT)-like, in GBM is associated with 83 tumor progression and therapy resistance (Bhat et al., 2013; Halliday et al., 2014; Phillips 84 intrinsic transcriptional subtype signatures and the single sample gene set enrichment 115 analysis (ssGSEA)-based equivalent distribution resampling classification strategy 116 (Wang et al., 2017) . Overall, 39% of the samples were identified as CL, 41% as MES and 117 20% as PN (Table S1 ). Principal component analysis showed a large overlap of the 118 transcription profile among CL and PN BTSCs while most of the MES BTSCs appeared 119 as a separate group ( Figure 1A) . Differential gene expression analysis comparing MES 120 versus Non-MES (PN and CL) BTSCs confirmed a clear separation among the two 121 groups, with the exception of a small number of cell lines that showed a mixed expression 122 profile ( Figure 1B and Table S2 ). 123
To reveal the signaling pathways underlying the differences among MES versus 124
Non-MES BTSCs we then applied a network-based approach based on ARACNe 125 (Algorithm for the Reconstruction of Accurate Cellular Networks) (Basso et al., 2005; 126 Carro et al., 2010) , which identifies a list of transcription factors (TFs) with their predicted 127 targets, defined as regulons. The regulon for each TF is constituted by all the genes whose 128 expression data exhibit significant mutual information with that of a given TF and are 129 thus expected to be regulated by that TF (Castro et al., 2016; Fletcher et al., 2013) . 130
Enrichment of a relevant gene signature in each of the regulons can point to the TFs acting 131 as master regulators (MRs) of the response or phenotype (Carro et al., 2010; Fletcher et 132 al., 2013) . Master regulator analysis (MRA), identified a series of TFs, among which 133 FOSL1, SOX11, OLIG2, CTCF and IRF1 were the top 5 most statistically significant 134 (Benjamini-Hochberg P < 0.0001) (Table S3 and Figure 1C ). FOSL1 and IRF1 were 135 significantly upregulated in the MES BTSCs, while SOX11, OLIG2, CTCF were 136 upregulated in the Non-MES BTSCs (Figure S1A and 1D). Gene set enrichment analysis 137 (GSEA) evidenced how the regulons for the top 5 TFs are enriched for genes that are 138 differentially expressed among the two classes (MES and Non-MES) with FOSL1 having 139 the highest enrichment score ( Figure 1C and Figure S1B ). 140
We then analyzed the TCGA pan-glioma dataset (Ceccarelli et al., 2016) and 141 observed that FOSL1 expression is elevated in the IDH-wt glioma molecular subtype 142 ( Figure 1E and Table S4 ) and that high expression levels are associated with worse 143 prognosis in IDH-wt GBM ( Figure 1F ), thus suggesting that FOSL1 could represent not 144 only a master regulator of the glioma-intrinsic MES signature, but also a putative key 145 player in MES GBM pathogenesis. 146 147 NF1 modulates the MES signature and FOSL1 expression 148 NF1 alterations and activation of the RAS/MAPK signaling have been previously 149 associated with the MES GBM subtype (Brennan et al., 2013; Verhaak et al., 2010; Wang 150 et al., 2016; Wang et al., 2017) . However, whether NF1 plays a functional role in the 151 regulation of the MES gene signature (MGS) still remains to be established. 152
We initially grouped, according to the previously described subtype-specific gene 153 signatures, a subset of IDH-wt GBM samples of the TCGA dataset for which RNA-seq 154 data were available (n = 152) (see methods for details). By analyzing the frequency of 155 NF1 alterations (either point mutations or biallelic gene loss) in the different subtypes 156 (Figure 2A ), we confirmed a significant enrichment of NF1 alterations in MES versus 157
Non-MES tumors (Fisher's Exact test P value = 0.03) ( Figure 2B ). Importantly, we 158 detected higher level of FOSL1 mRNA in the cohort of patient tumors with NF1 159 alterations, both low-grade gliomas (LGGs) and GBMs (Figures 2C and To test whether NF1 signaling is directly involved in the regulation of FOSL1 and 163 the MES subtype, we manipulated NF1 expression in patient derived tumorspheres of 164 either the MES or PN subtype ( Figure S3A -B). To recapitulate the activity of the full-165 length NF1 protein we transduced the cells with the NF1 GTPase-activating domain 166 (NF1-GRD), spanning the whole predicted Ras GTPase-activating (GAP) domain 167 (McCormick, 1990) . NF1-GRD expression in the MES cell line BTSC 233 led to 168 inhibition of RAS activity as confirmed by analysis of pERK expression upon EGF or 169 serum stimulation ( Figure S2A -B) as well as by RAS pull down assay ( Figure S2C ). 170 Furthermore, analysis of a RAS-induced oncogenic signature expression by GSEA 171 showed a strong reduction in NF1-GRD expressing cells (NES = -1.7; FDR q-value < 172 0.001) ( Figure S2D ). Most importantly, NF1-GRD expression led to a significant 173 reduction of the MGSs (Wang signature: NES = -1.3; FDR q-value = 0.05; Phillips 174 signature: NES = -1.7; FDR q-value < 0.001) ( Figure 2E , left panels). On the contrary, 175
Proneural gene signatures (PNGSs) were upregulated (Wang signature: NES = 1.2; FDR 176 q-value = 0.12; Phillips signature: NES = 1.3; FDR q-value = 0.1) ( Figure 2E , right 177 panels). Western blot analysis also revealed a significant decrease of CHI3L1 expression, 178 a well characterized mesenchymal marker, upon NF1-GRD overexpression ( Figure 2F ). 179
Mesenchymal glioblastoma cells are able to differentiate into osteocytes, a feature 180 they share with mesenchymal stem cells (Ricci-Vitiani et al., 2008; Tso et al., 2006) . 181
Consistent with the loss of the MGS, the ability to differentiate into osteocytes was lost 182 in the BTSC 233 MES cells transduced with the NF1-GRD, as documented by Alizarin 183
Red staining ( Figure 2G ). 184
To further confirm whether NF1 deletion could be sufficient to induce changes in 185 the MGS, we then knocked down NF1 in the NF1-expressing PN cell line BTSC 3021 186 ( Figure 2H ) and performed microarray gene expression analysis followed by GSEA. Both 187 Wang and Phillips MGSs were enriched upon NF1 silencing (Wang: NES = 1.61; FDR 188 q-value = 0.005; Phillips: NES = 1.9; FDR q-value < 0.001) ( Figure 2I ). The PNGSs 189 instead were not significantly lost (data not shown). 190
Taken together, our data indicate that NF1 modulation is able to alter the MGS 191 expression in GBM. NF1-led gene expression changes might be driven by an effect on 192 MGS master regulators. Alternatively, other TFs might be involved. We therefore 193 analyzed the expression of FOSL1 and other previously described mesenchymal TFs 194 (Bhat et al., 2011; Carro et al., 2010) NSCs model, Fosl1 expression was knocked out through sgRNAs. Efficient 229 downregulation of FRA-1 was achieved with 2 different sgRNAs ( Figure 3C ). Cells 230 transduced with sgFosl1_1 and sgFosl1_3 were then subjected to further studies. 231
As suggested by the data presented here on the human BTSCs datasets (Figures 232 1C-D and 2K), FOSL1 appears to be a key regulator the MES subtype. Consistently, 233 RNA-seq analysis followed by GSEA of p53-null Kras G12V sgFosl1_1 versus sgCtrl 234 revealed a significant loss of Wang and Phillips MGSs (Wang: NES = -1.85; FDR q-value 235 < 0.001; Phillips: NES = -1.91; FDR q-value < 0.001) ( Figure 3D , left panels). 236
Oppositely, Wang and Phillips PNGSs were increased in sgFosl1_1 cells (Wang: NES = 237 1.42; FDR q-value = 0.029; Phillips: NES = 2.10; FDR q-value < 0.001) ( Figure 3D , right 238 panels). These findings were validated by qRT-PCR with a significant decrease in 239 expression of a panel of MES genes (Plau, Itga7, Timp1, Plaur, Fn1, Cyr61, Actn1, 240 S100a4, Vim, Cd44) ( Figure 3E ) and increased expression of PN genes (Olig2, Ncam1, 241
Bcan, Lgr5) in the Fosl1 knock-out (KO) Kras G12V NSCs ( Figure 3F ). 242 243 Fosl1 deletion reduces stemness and tumor growth 244 Ras activating mutations have been widely used to study gliomagenesis, in 245 combination with other alterations as Akt mutation (Holland et al., 2000) , loss of 246 Ink4a/Arf (Uhrbom et al., 2002) or p53 (Friedmann-Morvinski et al., 2012; Koschmann 247 et al., 2016; Muñoz et al., 2013) . Thus, we then explored the possibility that Fosl1 could 248 modulate the tumorigenic potential of the p53-null Kras mutant cells. 249
Cell viability was significantly decreased in Fosl1 KO cell lines, as compared to 250 sgCtrl ( Figure 4A ). Concomitantly, we observed a significant decreased percentage of 251 cells in S-phase (mean values: sgCtrl = 42.6%; sgFosl1_1 = 21.6%, P ≤ 0.001; sgFosl1_3 252 = 20.4%, P = 0.003) and an increase in percentage of cells in G2/M (mean values: sgCtrl 253 = 11.7%, sgFosl1_1 = 28.4%, P ≤ 0.001; sgFosl1_3 = 23.4%, P = 0.012) ( Figure 4B ). 254
Another aspect that contributes to GBM aggressiveness is its heterogeneity, 255 attributable in part to the presence of glioma stem cells. By using limiting dilution assays, 256
we found that Fosl1 is required for the maintenance of stem cell capacity ( Figure 4C ). 257
Moreover, RNA-seq analysis showed that sgFosl1_1 cells downregulated the expression 258 of stem genes (Elf4, Klf4, Itgb1, Nes, Sall4, L1cam, Melk, Cd44, Myc, Fut4, Cxcr4, 259 Prom1) while upregulating the expression of lineage-specific genes: neuronal (Map2, 260 Ncam1, Tubb3, Slc1a2, Rbfox3, Dcx) , astrocytic (Aldh1l1, Gfap, S100b, Slc1a3) and 261 oligodendrocytic (Olig2, Sox10, Cnp, Mbp, Cspg4) ( Figure 4D ). The different expression 262 of some of the stem/differentiation markers was confirmed also by immunofluorescence 263 analysis. While Fosl1 KO cells presented low expression of the stem cell marker CD44, 264 differentiation markers as GFAP and OLIG2 were significantly higher when compared to 265 sgCtrl cells ( Figure 4E , Figure S4 ). 266
We then sought to test whether: i) p53-null Kras G12V NSCs were tumorigenic and 267 ii) Fosl1 played any role in their tumorigenic potential. Intracranial injections of p53-null 268
Kras G12V NSCs in nu/nu mice led to the development of high-grade tumors with a median 269 survival of 37 days in control cells (n=9). However, the sgFosl1_1 injected mice (n=6) 270 had a significant increase in median survival (54.5 days, Log-rank P = 0.0263) ( Figure 4G ). Similarly, when we compared 276 mRNA expression of a sgCtrl tumor with high FRA-1 expression (T4, Figure 4G In order to investigate if the MES phenotype induced with Fosl1 overexpression 304 would have any effect in vivo, p53-null Kras G12V Fosl1 tetON NSCs were intracranially 305 injected into syngeneic C57BL/6J wildtype mice. Injected mice were randomized and 306 subjected to Dox diet (food pellets and drinking water) or kept as controls with regular 307 food and drinking water with 1% sucrose. No differences in mice survival were observed 308 ( Figure S5B ). However, tumors developed from Fosl1 overexpressing mice (+Dox) were 309 larger ( Figure 5D ), more infiltrative and with a more aggressive appearance than controls 310 (-Dox), that mostly grew as superficial tumor masses, even if both -Dox and +Dox 311 tumors seem to proliferate similarly ( Figure S5C ). 312
Tumorspheres were derived from -Dox and +Dox tumor-bearing mice and Fosl1 313 expression was manipulated in vitro through addition or withdrawal of Dox from the 314 culture medium. In the case of tumorspheres derived from a -Dox tumor, when Dox was 315 added for 19 days, high levels of FRA-1 expression were detected by western blot (Figure  316 5E). At the mRNA level, Dox treatment also greatly increased Fosl1 expression, as well 317 as some of the MES genes ( Figure 5F ), while the expression of PN genes was 318 downregulated ( Figure 5G ). Conversely, when Dox was removed from +Dox derived 319 tumorspheres for 19 days, the expression of FRA-1 decreased ( Figure 5H -I), along with 320 the expression of MES genes ( Figure 5I ), while PN genes were upregulated ( Figure 5J ). 321
These results confirm the essential role of Fosl1 in the regulation of the MES gene 322 signature in p53-null Kras G12V tumor cells and the plasticity between the PN and MES 323 subtypes. 324
FOSL1 controls growth, stemness and MES gene expression in patient-derived 326 tumor cells 327
To prove the relevance of our findings in the context of human tumors, we 328 analyzed BTSC lines characterized as Non-MES (BTSC 268 and 409) or MES (BTSC 329 349 and 380) ( Figure 1A ). By western blot, we found that MES BTSC 380 did not express 330 NF1 while BTSC 349 showed a different pattern of NF1 expression compared to the Non-331 MES lines BTSC 268 and 409 (intact NF1), that might be due to a NF1 point mutation. Figure 6D ). Moreover, FOSL1 silencing resulted 343 also in the significant downregulation of the MES genes ( Figure 6E ), while no major 344 differences in the expression of PN genes was observed ( Figure S6B) . 345
Lastly, we tested whether FRA-1 modulates the MGS via direct target regulation. 346
To this end, we first identified high-confidence FOSL1/FRA-1 binding sites in chromatin 347 immunoprecipitation-seq (ChIP-seq) generated in non-mesenchymal cancer cells (see 348 methods) and then we determined the counts per million reads (CPM) of the enhancer 349 histone mark H3K27Ac in a set of MES and non-MES BTSCs (Mack et al., 2019) . The most broadly accepted transcriptional classification of GBM was originally 370 based on gene expression profiles of bulk tumors (Verhaak et al., 2010) , which did not 371 discriminate the contribution of tumor cells and TME to the transcriptional signatures. It 372 is now becoming evident that both cell-intrinsic and extrinsic cues can contribute to the 373 specification of the MES subtype (Bhat et al., 2013; Neftel et al., 2019; Wang et al., 2017) . 374
Bhat and colleagues had shown that while some of the MES GBMs maintained the 375 mesenchymal characteristics when expanded in vitro as BTSCs, some others lost the 376 MGS after few passages while exhibiting a higher PNGS (Bhat et al., 2013) . These data, 377 together with the evidence that xenografts into immunocompromised mice of BTSCs 378 derived from MES GBMs were also unable to fully restore the MES phenotype, suggested 379 that the presence of an intact TME potentially contributed to the maintenance of a MGS, 380 either by directly influencing a cell-intrinsic MGS or by expression of the TME-specific 381 signature. Recently, the transcriptional GBM subtypes were redefined based on the 382 expression of glioma-intrinsic genes, thus excluding the genes expressed by cells of the 383 TME (Wang et al., 2017) . Our master regulator analysis on the BTSCs points to the AP- subtype (Bhat et al., 2011; Carro et al., 2010) . While FOSL1 was also listed as a putative 388 MES master regulator (Carro et al., 2010) , its function and mechanism of action have not 389 been further characterized since then. Our experimental data show that FOSL1 is a key 390 regulator of GBM subtype plasticity and MES transition, and define the molecular 391 mechanism through which FOSL1 is regulated. 392
Although consistently defined, GBM subtypes do not represent static entities. The 393 plasticity between subtypes happens at several levels. Besides the referred MES-to-PN 394 change in cultured GSCs compared to the parental tumor (Bhat et al., 2013) , a PN-to-395 MES shift often occurs upon treatment and recurrence. Several independent studies 396 comparing matched pairs of primary and recurrent tumors demonstrated a tendency to 397 shift towards a MES phenotype, associated with a worse patient survival, likely as a result 398 of treatment-induced changes in the tumor and/or the microenvironment (Phillips et al., 399 2006; Wang et al., 2016; Wang et al., 2017) . Moreover, distinct subtypes/cellular states, 400 can coexist within the same tumor (Neftel et al., 2019; Patel et al., 2014; Sottoriva et al., 401 2013; Wang et al., 2019) and targeting these multiple cellular components could result in 402 more effective treatments (Wang et al., 2019) . 403 PN-to-MES transition is often considered an EMT-like phenomenon, associated 404 with tumor progression (Fedele et al., 2019) . The role of FOSL1 in EMT has been studied 405 in other tumor types. In breast cancer cells FOSL1 expression correlates with 406 mesenchymal features and drives cancer stem cells (Tam et al., 2013) and the regulation 407 of EMT seems to happen through the direct binding of FRA-1 to promoters of EMT genes 408 such as Tgfb1, Zeb1 and Zeb2 (Bakiri et al., 2015) . In colorectal cancer cells, FOSL1 was 409 also shown to promote cancer aggressiveness through EMT by direct transcription 410 regulation of EMT-related genes (Diesch et al., 2014; Liu et al., 2015) . 411
It is well established that NF1 inactivation is a major genetic event associated with 412 the MES subtype (Verhaak et al., 2010; Wang et al., 2017) . However, this is probably a 413 late event in MES gliomagenesis, as all tumors possibly arise from a PN precursor and 414 just later in disease progression acquire NF1 alterations that are directly associated with 415 a transition to a MES subtype (Ozawa et al., 2014) . Moreover, NF1 deficiency has been 416 recently linked to macrophage/microglia infiltration in the MES subtype (Wang et al., 417 2017) . The fact that the enriched macrophage/microglia microenvironment is also able to 418 modulate a MES phenotype suggests that there might be a two-way interaction between 419 tumor cells and TME. The mechanisms of NF1-regulated chemotaxis and whether this 420 relationship between the TME and MGS in GBM is causal remain elusive. 421
Here we provide evidence that manipulation of NF1 expression levels in patient-422 derived BTSCs has a direct consequence on the tumor-intrinsic MGS activation and that 423 such activation, can at least in part be mediated by the modulation of FOSL1. Among the 424 previously validated MRs, only CEBPB appears also to be finely modulated by NF1 425 inactivation. This suggests that among the TFs previously characterized (such as FOSL2, 426 STAT3, BHLHB2 and RUNX1), FOSL1 and CEBPB might play a specific role in the NF1-427 mediated MES transition that occurs in glioma cells with limited or possibly absent effect 428 by the TME. However, whether FOSL1 contributes also to the putative cross-talk between 429 the TME and the cell-intrinsic MGS, will still have to be established. 430
Furthermore we show that FOSL1 is a crucial player in glioma pathogenesis, 431 particularly in a MAPK-driven MES GBM context. Our findings broaden its previously 432 described role in KRAS-driven epithelial tumors, such as lung and pancreatic ductal 433 adenocarcinoma (Vallejo et al., 2017) . NF1 inactivation results in Ras activation, which 434 stimulates downstream pathways as MAPK and PI3K/Akt /mTOR. RAS/MEK/ERK 435 activation in turn regulates FOSL1 mRNA expression and FRA-1 protein stability 436 (Casalino et al., 2003; Verde et al., 2007) . FRA-1 can then directly bind and activate some 437 of the MES genes, while possibly binding its own promoter to activate its own expression 438 (Diesch et al., 2014; Lau et al., 2016) . This generates a feedback loop that induces MGS, 439 increases proliferation and stemness, sustaining tumor growth. FRA-1 requires, for its 440 transcriptional activity, heterodimerization with the AP-1 transcription factors JUN, 441 JUNB or JUND (Eferl and Wagner, 2003) . We would like to thank Álvaro Ucero for his input on the project and Flora A. 453
Díaz for her technical support. We are grateful to Francisco X. Real and Scott Lowe for 454 critical input on the manuscript. We thank Pamela Franco for experimental support and 455 discussion. This work was supported by a grant from the Marie Curie International re-456 integration Grants (MC-IRG), project nr. 268303 (to M.S.C.) and by grants from the 457 ISCIII, project PI13/01028, cofounded by the European Regional Development Human Genome U219 microarrays from GSE67089 (Mao et al., 2013) and 17 Affymetrix 478 HG-U133 Plus 2.0 microarrays from GSE8049 (Günther et al., 2008) . For the previously 479 published data, at exception of the GSE119834, for which pre-processed data were used, 480 raw data were downloaded from the GEO repository 481 (https://www.ncbi.nlm.nih.gov/geo/) and subsequently the 'affy' package (R 482 programming language) was used for robust multi-array average normalization followed 483 by quantile normalization. For genes with several probe sets, the median of all probes had 484 been chosen and only common genes among all the datasets (n = 14821) were used for 485 further analysis. To avoid issues with the use of different transcriptomic platforms each 486 dataset was then scaled (mean = 0, sd = 1) before assembling the combined final dataset. 487
Transcriptional subtypes were obtained using the 'ssgsea.GBM.classification' R package 488 (Wang et al., 2017) , through the SubtypeME tool of the GlioVis web portal 489 (http://gliovis.bioinfo.cnio.es) (Bowman et al., 2017) . Differential gene expression (MES 490 vs Non-MES BTSCs) was performed using the 'limma' R package. 491
The master regulator analysis was performed using the 'RTN' R package (Castro 492 et al., 2016) . Normalized BTSC expression data were used as input to build a 493 transcriptional network (TN) for 785 TFs present in the dataset. TF annotations were 494 obtained from Gene Ontology (GO:0003700). P values for network edges were computed 495 from a pooled null distribution using 1000 permutations. Edges with an adjusted-P value 496 < 0.05 were kept for data processing inequality (DPI) filtering. In the TN, each target can 497 be connected to multiple TFs and regulation can occur as a result of both direct and 498 indirect interactions. DPI-filtering removes the weakest interaction in any triangle of two 499
TFs and a target gene, therefore preserving the dominant TF-target pairs and resulting in 500 a filtered TN that highlights the most significant interactions (Fletcher et al., 2013) . Post-501 DPI filtering, the MRA computes the overlap between the transcriptional regulatory 502 unities (regulons) and the input signature genes using the hypergeometric distribution 503 (with multiple hypothesis testing corrections). To identify master regulators, the 504 differential gene expression between MES and Non-MES was used as a phenotype. 505 506 TCGA pan-glioma data analysis 507 RSEM normalized RNA-seq data for the TCGA GBMLGG dataset were 508 downloaded from the Broad Institute Firebrowse (http://gdac.broadinstitute.org). NF1 509 copy number alterations and point mutations were obtained at the cBioPortal 510 (https://www.cbioportal.org). Transcriptional subtypes were inferred using the 511 'ssgsea.GBM.classification' R package as indicated above. Glioma molecular subtypes 512 information was downloaded from the GlioVis web portal (http://gliovis.bioinfo.cnio.es) 513 (Bowman et al., 2017) . Survival analysis was performed using the 'survival' R package. 514 515
Gene Expression Array and gene set enrichment analysis (GSEA) 516
For gene expression profiling of the BTSC lines of the Freiburg dataset, total RNA 517 was prepared using the RNeasy kit (Qiagen #74104) or the AllPrep DNA/RNA/Protein 518 mini kit (Qiagen #80004) and quantified using 2100 Bioanalyzer (Agilent). One-and-a-519 half µg of total RNA for each sample was sent to the genomic facility of the German 520
Cancer Research Center (DKFZ) in Heidelberg (Germany) where hybridization and data 521 normalization were performed. Hybridization was carried out on Illumina HumanHT-522 12v4 expression BeadChip. Gene set enrichment analysis was performed using the GSEA 523 software (http://www.broadinstitute.org/gsea/index.jsp). 524 525
ChIP-seq analysis 526
We downloaded FOSL1 ChIP-seq profiling from ENCODE tracks ENCFF000OZR and 527 ENCFF000OZQ. OLIG2 binding sites and ChIP-seq profiles were downloaded from 528 GEO: GSM1306365_MGG8TPC.OLIG2r1c and GSM1306367_MGG8TPC.OLIG2r2. 529
H3K27Ac data were downloaded from GSE119755 (Mack et al., 2019) for 530 GSM3382291_GSC17, GSM3382343_GSC40, GSM3382319_GSC3, 531 GSM3382321_GSC30, GSM3382341_GSC4, GSM3382277_GSC10. Scatter plots were 532 generated with Seqmonk v1.45 using FOSL1 binding sites in MES-BTSCs using a 533
Kolmorogov-Smirnov test with a sample size of 297 when constructing the control 534 distributions and filtering by maximum P value of 0.05 (multiple testing correction 535 applied). Minimum absolute z-score was 0.5. A custom regression was calculated. 536
Quantitation was Read Count Quantitation using all reads correcting for total count only 537 in probes to largest store log transformed duplicates ignored. Heatmaps were generated 538 using ChaSE, using either FOSL1 or OLIG2 binding sites with ±10,000 bp. 539 540
Mouse strains and husbandry 541
GFAP-tv-a; hGFAP-Cre; Rosa26-LSL-Cas9 mice were previously described 542 (Oldrini et al., 2018) . Patient-derived glioblastoma stem cells (BTSCs) were prepared from tumor 577 specimens under IRB-approved guidelines as described before (Fedele et al., 2017) . 578
BTSCs were grown as neurospheres in Neurobasal medium (Gibco #10888022) 579 containing B27 supplement (Gibco #12587010), N2 supplement (Gibco #17502048), b-580 FGF (20 ng/mL), EGF (20 ng/mL), LIF (10 ng/mL, CellGS #GFH200-20), 2 µg/mL 581 Heparin and L-glutamine (2mM). JX6 were kindly provided by Y. Gillespie (UAB, 582 Birmingham). 583 584
Vectors, virus production and infection 585
Flag-tagged NF1-GRD (aminoacids 1131-1534) was amplified by PCR from 586 human cortical tissue (epilepsy patient) and first cloned in the pDRIVE vector. Primers 587 are listed in Table S5 . The NF1-GRD sequence was then excised by restriction digestion 588 using PmeI and SpeI enzymes and subcloned in the modified pCHMWS lentiviral vector 589 (kind gift from V. Baekelandt, University of Leuven, Belgium) sites by removing the 590 fLUC region. The correct sequence was verified by sequencing. For NF1 silencing, NF1 591 short hairpin from pLKO (Sigma, TRCN0000238778) vector was subcloned in pGIPZ 592 lentiviral vector (Open Biosystems). The corresponding short hairpin sequence was 593 synthetized (GATC) and amplified by PCR using XhoI and EcoRI sites containing 594 primers. The PCR product was digested using XhoI and EcoRI and subcloned into the 595 pGIPZ vector previously digested with XhoI and PmeI following by digestion with 596
EcoRI. The two vector fragments were ligated with NF1 short hairpin fragment. The 597 correct insertion and sequence was validated by sequencing. In addition, experiments 598 were performed using shNF1-pGIPZ clone V2LHS_76027 (clone 4) and V2LHS_260806 599 (clone 5). 600 The pLVX-Cre and respective control vector were kindly provided by Dr. Maria 615 Blasco (CNIO) and used to transduce Fosl1 TetON NSCs; pLKO.1-TET-shFOSL1 and 616 respective control vector were a gift from Dr. Silve Vicent (CIMA, Navarra University). 617
RCAS viruses (RCAS-shNf1, RCAS-sgNf1 and RCAS-Kras
Gp2-293 packaging cell line (Clontech #631458) was grown in DMEM (Sigma-618 Aldrich #D5796) with 10% FBS. Lentiviruses generated in this cell line were produced 619 using calcium-phosphate precipitate transfection and co-transfected with second-620 generation packaging vectors (pMD2G and psPAX2). High-titer virus was collected at 621 36 and 60 h following transfection. 622
All cells were infected with lenti-or retroviruses by four cycles of spin infection 623 (200 × g for 2 h), in presence of 8 µg/mL polybrene (Sigma-Aldrich #H9268). Transduced 624 cells were selected after 48 h from the last infection with 1 µg/mL Puromycin (Sigma-625 Aldrich #P8833). 626 627 Generation of murine gliomas 628 p53-null Kras G12V NSCs (5×10 5 cells) were injected intracranially into 4 to 5 629 weeks-old immunodeficient nu/nu mice. 630
Fosl1 TetON NSCs (5×10 5 cells) were intracranially injected into 4 to 5 weeks-old 631 wildtype C57Bl/6J mice that were fed ad libitum with 2 g/kg doxycycline-containing 632 pellets. Due to the limited penetration of the blood brain barrier and to insure enough Dox 633 was reaching the brain, 2 mg/mL Dox (PanReac AppliChem #A29510025) was also 634 added to drinking water with 1% sucrose (Sigma-Aldrich #S0389) (Annibali et al., 2014; 635 Mansuy and Bujard, 2000) . Control mice were kept with regular food and 1% sucrose 636 drinking water. 637
Mice were anaesthetized with 4% isofluorane and then injected with a stereotactic 638 apparatus (Stoelting) as previously described (Hambardzumyan et al., 2009) . After 639 intracranial injection, all mice were routinely checked and sacrificed when developed 640 symptoms of disease (lethargy, poor grooming, weight loss and macrocephaly). 641 642 Immunohistochemistry 643
Tissue samples were fixed in 10% formalin, paraffin-embedded and cut in 3 µm 644 sections, which were mounted in Superfrost Plus microscope slides (Thermo Scientific 645 #J1810AMNZ) and dried. Tissues were deparaffinized in xylene and re-hydrated through 646 graded concentrations of ethanol in water, ending in a final rinse in water. 647
For histopathological analysis, sections were stained with hematoxylin and eosin 648 (H&E). 649
For immunohistochemistry, deparaffinized sections underwent heat-induced 650 antigen retrieval, endogenous peroxidase activity was blocked with 3% hydrogen 651 peroxide (Sigma-Aldrich #H1009) for 15 min and slides were then incubated in blocking 652 solution (2.5% BSA (Sigma-Aldrich #A7906) and 10% Goat serum (Sigma-Aldrich 653 #G9023), diluted in PBS) for at least 1 h. Incubations with anti-FRA-1 (Santa Cruz #sc-654 183, 1:100) and anti-CD44 (BD Biosciences #550538, 1:100) were carried out overnight 655 at 4°C. Slides were then incubated with secondary anti-rabbit (Vector #BA-1000) or anti-656 Reverse Transcription Kit (Applied Biosystems #4368814). Quantitative PCR was 691 performed using the SYBR Select Master Mix (Applied Biosystems #4472908) according 692 to the manufacturer's instructions. qPCRs were run and the melting curves of the 693 amplified products were used to determine the specificity of the amplification. The 694 threshold cycle number for the genes analyzed was normalized to GAPDH. Mouse and 695 human primer sequences are listed in Table S5 . first with 1% BSA in PBS, then with PBS only and stained overnight with 50 µg/mL PI 717 (Sigma-Aldrich #P4170) and 100 µg/mL RNase A (Roche #10109142001) in PBS. 718
Samples were acquired in a FACSCanto II cytometer (BD Biosciences) and data were 719 analyzed using FlowJo software. 720 721
BrdU incorporation 722
Cells were pulse-labelled with 10 µM BrdU (Sigma-Aldrich #B9285) for 2 h, 723 harvested and washed twice with PBS prior to fixation with 70% ethanol cold ethanol, 724 added drop-wise to the cell pellet while vortexing. DNA denaturation was performed by 725 incubating samples for 10 min on ice with 0.1 M HCl with 0.5% Tween-20 and samples 726 were then resuspended in water and boiled at 100°C for 10 min. Anti-BrdU-FITC 727 antibody (BD Biosciences #556028) was incubated according to manufacturer's protocol. 728
After washing with PBSTB (PBS with 0.5% Tween-20 and 1% BSA), samples were 729 resuspended in 25 µg/mL PI and 100 µg/mL RNase A diluted in PBS. Samples were 730 acquired in a FACSCanto II cytometer (BD Biosciences) and data were analyzed using 731 FlowJo software. 732
733
Immunofluorescence 734
Cells were plated in laminin-coated coverslips and fixed with 4% PFA for 15 min. 735
Cells were then permeabilized with 0.1% Triton X-100 in 0.2% BSA and coverslips were 736 washed and blocked with 10% donkey serum in 0.2% BSA for 1 h. The following primary 737 antibodies were incubated overnight at 4°C: CD44 (BD Biosciences #550538, 1:100), 738 GFAP (Millipore #MAB360, 1:400) and OLIG2 (Millipore #AB9610, 1:100). Secondary 739 antibodies at 1:400 dilution (from Invitrogen, Alexa-Fluor anti-rabbit-488, anti-mouse-740 488 and anti-rat 594) were incubated for 1 h at RT and after washing coverslips were 741 incubated for 4 min with DAPI (1:4000, Sigma-Aldrich #D8417) and mounted with 742 ProLong Gold Antifade reagent (Invitrogen #P10144). 743
Fluorescence signal was quantified as the ratio of green/red pixel area relative to 744 DAPI pixel area per field of view, in a total of 36 fields per condition analyzed. 745 746
Neurosphere formation assay and limiting dilution analysis 747
Neurospheres were dissociated and passed through a 40 µm mesh filter to 748 eliminate non-single cells. Decreasing cell densities were plated in ultra-low attachment 749 96-well plates (Corning #CLS3474) and fresh medium was added every 3-4 days. The 750 number of positive wells for presence of spheres was counted 2 weeks after plating. 751
Limiting dilution analysis was performed using ELDA R package 752 (http://bioinf.wehi.edu.au/software/elda/). 753
754

RNA-sequencing and analysis on mouse NSCs 755
One microgram of total RNA from the samples was used. cDNA libraries were 756 prepared using the "QuantSeq 3' mRNA-Seq Library Prep Kit (FWD) for Illumina" 757 (Lexogen #015) by following manufacturer instructions. Library generation is initiated 758 by reverse transcription with oligo(dT) priming, and a second strand synthesis is 759 performed from random primers by a DNA polymerase. Primers from both steps contain 760
Illumina-compatible sequences. Adapter-ligated libraries were completed by PCR, 761 applied to an Illumina flow cell for cluster generation and sequenced on an Illumina 762 HiSeq 2500 by following manufacturer's protocols. Sequencing read alignment and 763 quantification and differential gene expression analysis was performed in the Bluebee 764 Genomics Platform, a cloud-based service provider (www.bluebee.com). Briefly, reads 765 were first trimmed with bbduk from BBTools (BBMap -Bushnell B, 766 https://sourceforge.net/projects/bbmap/) to remove adapter sequences and polyA tails. 767
Trimmed reads were aligned to the GRCm38/mm10 genome assembly with STAR v 2.5 768 (Dobin et al., 2013) . Read counting was performed with HTSeq (Anders et al., 2015) . 769 Differential gene expression analysis was performed with DESeq2 (Love et al., 2014) . 770
The list of stem/differentiation markers was compiled by combining a previously 771 described gene list (Sandberg et al. 2013 ) with other markers (Bazzoli et al., 2012) . 772
GSEAPreranked (Subramanian et al., 2005 ) was used to perform gene set enrichment 773 analysis of the described indicated signatures on a pre-ranked gene list, setting 1000 gene 774 set permutations. 775 776
Osteogenesis Differentiation Assay 777
The osteogenesis differentiation assay was performed using the StemPro 778
Osteogenesis Differentiation Kit (Life Technologies #A1007201) according to the 779 manufacturer's instructions. Briefly, 5´10 3 cells/cm 2 were seeded on laminin-coated 780 glass coverslips in a 24-well cell culture plate. Cells were incubated in MSC Growth 781 Medium at 37°C, 5% CO2 for 21 days, replacing the medium every 4 days. Cells were 782 then fixed with 4% formaldehyde, stained with Alizarin Red S solution (pH 4.2) and 783 mounted on microscope slides. Pictures were acquired using an Axiovert Microscope 784 (Zeiss). 785 786 Active Ras pull down assay 787 Active Ras pull down assay was performed using Active Ras pull down assay kit 788 (ThermoFisher Scientific #16117) according to the manufacturer's instructions. Briefly, 789 cells were grown in 10 cm plates at 80-90% confluency in presence or absence of growth 790 factors (EGF, FGF and LIF), and lysed with the provided buffer. Lysates were incubated 791 with either GDP or GTP for 30 min followed by precipitation with Western blot was performed with the provided anti-RAS antibody (1:250). 
Statistical analysis 821
All statistical analyses were performed using R programming language. Statistical 822 differences between groups in the in vitro assays were assessed by unpaired two-tailed 823 Student's t tests, unless otherwise specified. 824
Kaplan-Meier survival curves were produced with GraphPad Prism and P values 825 were generated using the Log-Rank statistics. 826
Results are presented as mean ± standard deviation (SD), and statistical 827 significance was defined as P ≤ 0.05 for a 95% confidence interval. 828 829 Data and code availability 830
The accession numbers for data reported in this paper are GEO: GSE137310 831 (Freiburg BTSCs) and GSE138010 (mouse NSCs). All the code used for data analysis 832 and plots generation will be available at: https://github.com/squatrim/Marques2019. 833 834 835 glioma. Genes Dev. 25, 2594 Dev. 25, -2609 Bhat, K.P.L., Balasubramaniyan, V., Vaillant, B., Ezhilarasan, R., Hummelink, K., 867 Hollingsworth, F., Wani, K., Heathcock, L., James, J.D., Goodman, L.D., et al. (2013) . 868
Mesenchymal Differentiation Mediated by NF-κB Promotes Radiation Resistance in 869 Glioblastoma. Cancer Cell 24, [331] [332] [333] [334] [335] [336] [337] [338] [339] [340] [341] [342] [343] [344] [345] [346] Bowman, R.L., Wang, Q., Carro, A., Verhaak, R.G.W., and Squatrito, M. (2017) . 871
GlioVis data portal for visualization and analysis of brain tumor expression datasets. 872 Neuro. Oncol. 19, [139] [140] [141] Brennan, C.W., Verhaak, R.G.W., McKenna, A., Campos, B., Noushmehr, H., Salama, 874 S.R., Zheng, S., Chakravarty, D., Sanborn, J.Z., Berman, S.H., et al. (2013) . The 875 somatic genomic landscape of glioblastoma. Cell 155, [462] [463] [464] [465] [466] [467] [468] [469] [470] [471] [472] [473] [474] [475] [476] [477] Carro, M.S., Lim, W.K., Alvarez, M.J., Bollo, R.J., Zhao, X., Snyder, E.Y., Sulman, 877 E.P., Anne, S.L., Doetsch, F., Colman, H., et al. (2010) . The transcriptional network for 878 mesenchymal transformation of brain tumours. Nature 463, [318] [319] [320] [321] [322] [323] [324] [325] Casalino, L., De Cesare, D., and Verde, P. (2003) . Accumulation of Fra-1 in ras-880
Transformed Cells Depends on Both Transcriptional Autoregulation and MEK-881 Dependent Posttranslational Stabilization. Mol. Cell. Biol. 23, 4401-4415. 882 Castro, M.A.A., de Santiago, I., Campbell, T.M., Vaughn, C., Hickey, T.E., Ross, E., 883 Tilley, W.D., Markowetz, F., Ponder, B.A.J., and Meyer, K.B. (2016) . Regulators of 884 genetic risk of breast cancer identified by integrative network analysis. Nat. Genet. 48, Ceccarelli, M., Barthel, F.P., Malta, T.M., Sabedot, T.S., Salama, S.R., Murray, B.A., 887 Morozova, O., Newton, Y., Radenbaugh, A., Pagnotta, S.M., et al. (2016) . Molecular 888
Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse 889
Glioma. Cell 164, [550] [551] [552] [553] [554] [555] [556] [557] [558] [559] [560] [561] [562] [563] Chen, J., Li, Y., Yu, T.S., McKay, R.M., Burns, D.K., Kernie, S.G., and Parada, L.F. 891 (2012) . A restricted cell population propagates glioblastoma growth after chemotherapy. 892 Nature 488, [522] [523] [524] [525] [526] Chiappetta, G., Ferraro, A., Botti, G., Monaco, M., Pasquinelli, R., Vuttariello, E., 894 
Figure 3. Fosl1 is induced by MAPK kinase activation and is required for MES gene expression. A)
Western blot analysis using the specified antibodies of p53-null NSCs, parental and infected with sgNf1, shNf1 and Kras G12V ; Vinculin used as loading control. B) mRNA expression of Fosl1 and MES genes (Plau, Plaur, Timp1 and Cd44), in infected p53-null NSCs, compared to parental cells (not infected). Data from a representative of two experiments are presented as mean ± SD (n=3), normalized to Gapdh expression. Student's t test, relative to parental cells: ns = not significant, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. C) FRA-1 expression detected by Western blot in p53-null Kras G12V NSCs upon transduction with sgRNAs targeting Fosl1, after selection with 1 µg/mL puromycin; Vinculin used as loading control. D) GSEA of p53-null Kras G12V sgFosl1_1 versus sgCtrl NSCs. Gene signatures from Wang and Phillips studies were analyzed (MES, left panels; PN, right panels). E) and F) mRNA expression of MES and PN genes, respectively, in sgCtrl and sgFosl1_1 p53-null Kras G12V NSCs. Data from a representative of two experiments are presented as mean ± SD (n=3), normalized to Gapdh expression. Student's t test, relative to sgCtrl: *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
Figure 4. Fosl1 knock-out impairs cell growth and stemness in vitro and increases survival in a xenograft model. A)
Cell viability of control and Fosl1 KO p53-null Kras G12V NSCs measured by MTT assay; absorbance values were normalized to day 1. Data from a representative of three independent experiments are presented as mean ± SD (n=10). Student's t test on day 7, relative to sgCtrl: ***P ≤ 0.001. B) Quantification of cell cycle populations of control and Fosl1 KO p53-null Kras G12V NSCs by flow cytometry analysis of PI staining. Data from a representative of two independent experiments are presented as mean ± SD (n=3). Student's t test, relative to sgCtrl: *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001. C) A representative limiting dilution experiment on p53-null Kras G12V sgCtrl and sgFosl1_1 NSCs, calculated with extreme limiting dilution assay (ELDA) analysis; P < 0.0001. D) Heatmap of expression of stem cell (yellow) and lineage-specific (neuronal -purple, astrocytic -green and oligodendrocyticorange) genes, comparing sgCtrl and sgFosl1_1 p53-null Kras G12V NSCs. E) Quantification of pixel area (fold change relative to sgCtrl) of CD44, GFAP and OLIG2 relative to DAPI pixel area per field of view in control and Fosl1 KO p53-null Kras G12V NSCs. Data from a representative of two independent experiments; Student's t test, relative to sgCtrl: ***P ≤ 0.001. F) Kaplan-Meier survival curves of nu/nu mice injected with p53-null Kras G12V sgCtrl (n=9) and sgFosl1_1 (n=6) NSCs. Log-rank P = 0.0263. G) Western blot analysis using the indicated antibodies of 4 sgCtrl and 4 sgFosl1_1 tumors (showing low or no detectable expression of FRA-1); Vinculin used as loading control. H) Representative images of IHCs using the indicated antibodies. Scale bars represent 100 µm. I) mRNA expression of MES genes in the samples sgCtrl-T4 (higher FRA-1 expression) and sgFosl1_1-T3 and -T4 (no detectable FRA-1 expression). J) mRNA expression of PN genes in samples as in (H). Data from a representative of two experiments are presented as mean ± SD (n=3), normalized to Gapdh expression. Student's t test for sgFosl1_1 tumors, relative to sgCtrl-T4: ns = not significant, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. See also Figure S4 . 
IRES-EGFP
; Col1a1 TetO-Fosl1 mice, upon in vitro infection with Cre and induction of Fosl1 overexpression with 1 µg/mL Dox for 72 h; Vinculin used as loading control. B) mRNA expression of Fosl1 and MES genes in Fosl1 tetON p53-null Kras G12V cells upon 72 h induction with 1 µg/mL Dox. C) mRNA expression of PN genes in Fosl1 tetON p53-null Kras G12V cells upon 72 h induction with 1 µg/mL Dox. D) Quantification of tumor area (µm 2 ) of -Dox and +Dox tumors (n=8/8). For each mouse, the brain section on the H&E slide with a larger tumor was considered and quantified using the ZEN software (Zeiss). E) Western blot detection of FRA-1 expression in tumorspheres derived from a control (−Dox) tumor. Tumorspheres were isolated and kept without Dox until first passage, when 1 µg/mL Dox was added and kept for 19 days (+Dox in vitro). F) mRNA expression of Fosl1 and MES genes in tumorspheres in absence or presence of Dox for 19 days. G) mRNA expression of PN genes in tumorspheres in absence or presence of Dox for 19 days. H) Western blot detection of FRA-1 expression in tumorspheres derived from a Fosl1 overexpressing (+Dox) tumor. Tumorspheres were isolated and kept with 1 µg/mL Dox until first passage, when Dox was removed for 19 days (−Dox in vitro). I) mRNA expression of Fosl1 and MES genes in tumorspheres in presence or absence of Dox for 19 days. J) mRNA expression of PN genes in tumorspheres in presence or absence of Dox for 19 days. qPCR data from a representative of two experiments are presented as mean ± SD (n=3), normalized to Gapdh expression. Student's t test, relative to the respective control (−Dox in B, C, F and G; +Dox in I and J): ns = not significant, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. See also Figure S5 . Figure 6 . FOSL1 silencing in a patient-derived MES tumor stem cell line decreases cell growth, stemness and MGS in vitro. A) Western blot analysis using the specified antibodies of human brain tumor stem cell lines, characterized as Non-MES (left) and MES (right). B) Western blot detection of FRA-1 in MES BTSC 349 upon transduction with inducible shRNAs targeting GFP (control) and FOSL1, analyzed after 3 and 7 days of Dox treatment; Vinculin used as loading control. C) Cell growth of BTSC 349 shGFP and shFOSL1, in absence or presence of Dox, measured by MTT assay; absorbance values were normalized to day 1. Data from a representative of three independent experiments are presented as mean ± SD (n=15). Student's t test on day 7, relative to shFOSL1 -Dox: ***P ≤ 0.001. D) Representative limiting dilution analysis on BTSC 349 shFOSL1, in presence or absence of Dox, calculated with extreme limiting dilution assay (ELDA) analysis; P < 0.0001. E) mRNA expression of FOSL1 and MES genes in BTSC 349 shFOSL1 in absence or presence of Dox for 3 days. Data from a representative of three experiments are presented as mean ± SD (n=3), normalized to GAPDH expression. Student's t test, relative to -Dox: ns = not significant, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. F) Scatter plot of H3K27Ac NANOG gene was used as a negative control. Student's t test, relative to IgG: ns = not significant, **P ≤ 0.01, ***P ≤ 0.001. See also Figure S6 . (BTSC 3021 and 3047) . C) and D) qRT-PCR analysis of mesenchymal genes master regulators expression (BHLHB2, CEBPB, FOSL2, RUNX1, STAT3 and TAZ) upon NF1-GRD overexpression in BTSC 233 (C) or NF1 knockdown in 3021 cells (D). Data are presented as mean ± SD (n=3), normalized to GAPDH or 18s rRNA expression; Student's t test, ns = not significant, *P ≤ 0.05. E) GSEA of FOSL1 targets signature in GBMs with NF1 alteration or wt status (top panel), BTSC 3021 cells transduced with shNF1 or shCtrl (middle panel), and BTSC 233 cells transduced with NF1-GRD or Ctrl vector (bottom panel). F) and G) qRT-PCR analysis of known mesenchymal FOSL1 targets (ITGA3, ITGA5, PLAU, SERPINE1 and TNC) in BTSC 233 and 232 cells transduced with NF1-GRD expressing lentivirus (F) and BTSC 3021 and 3047 cells transduced with shNF1 expressing lentivirus. Data are presented as mean ± SD (n=3), normalized to 18s rRNA expression; Student's t test, ns = not significant, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. 
